Cambridge, MA, United States of America

Liang Schweizer

This inventor holds 1 USPTO granted patent and 13 published patent applications. Top assignee: Hifibio (Hk) Limited. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Liang Schweizer. Retrieved from https://idiyas.com/inventor/liang-schweizer-5ry1i7ql

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Liang Schweizer

Introduction

Liang Schweizer is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly through his innovative work on antibodies.

Latest Patents

Schweizer holds a patent for an "ANTI-GALECTIN-9 ANTIBODY AND USES THEREOF." This patent highlights his expertise in developing therapeutic solutions that target specific proteins, which can have profound implications in medical treatments.

Career Highlights

Liang Schweizer is currently associated with Hifibio (HK) Limited, where he continues to push the boundaries of scientific research and innovation. His work is characterized by a commitment to advancing healthcare through biotechnology.

Collaborations

He collaborates with notable colleagues, including Germain Margall Ducos and Rachel Pacherie, who contribute to his research endeavors and enhance the impact of his inventions.

Conclusion

Liang Schweizer's contributions to biotechnology, particularly through his patent on anti-galectin-9 antibodies, exemplify his role as an innovative inventor in the field. His work continues to inspire advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…